FILSUVEZ (birch triterpenes gel)

Self-Administration – topical

Diagnosis considered for coverage:
  • Diagnosis: Indicated for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa in adult and pediatric patients 6 months of age and older
Coverage Criteria:

For diagnosis of epidermolysis bullosa:

  • Diagnosis of one of the following:
    • Dystrophic epidermolysis bullosa (DEB)
    • Junctional epidermolysis bullosa (JEB), AND
  • Disease is confirmed by one of the following:
    • Genetic testing confirms mutation in one of the following genes:
      • For Dystrophic epidermolysis bullosa (DEB), collagen type VII (COL7A1), OR
      • For Junctional epidermolysis bullosa (JEB), one of the following:
        • ITGA6
        • ITGB4
        • collagen type XVII (COL17A1)
        • LAMA3
        • LAMB3
        • LAMC2
        • ITGA3
        • LAMA3A, OR
    • Skin biopsy, AND
  • Patient is 6 months of age or older, AND
  • Medication is being used for the treatment of wounds, AND
  • DEB or JEB associated wounds are present for at least 21 days, AND
  • Patient does not have signs of infection for wound being treated, AND
  • Patient has no evidence or history of basal or squamous cell carcinoma for wound being treated, AND
  • Patient does not have history of stem cell transplant, AND
  • Medication is not being used concurrently with other FDA approved therapies (e.g.,Vyjuvek) for the treatment epidermolysis bullosa, AND
  • Standard wound care management not adequate in healing wounds (e.g., daily wound dressings, pain management, controlling infections), AND
  • Prescribed by or in consultation with a specialist with expertise in wound care
Reauthorization Criteria:

For diagnosis of epidermolysis bullosa:

  • Patient demonstrates positive clinical response to therapy as evidenced by wound is healing but not completely closed; AND
  • Patient does not have signs of infection for wound being treated; AND
  • Patient has no evidence or history of basal or squamous cell carcinoma for wound being treated; AND
  • Prescribed by or in consultation with a specialist with expertise in wound care
Coverage Duration:
  • Initial: 3 months
  • Reauthorization: 6 months
Dosing:

For diagnosis of epidermolysis bullosa:

  • Apply a 1 mm layer of Filsuvez to the affected wound surface only
Authorization is not covered for the following:

The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.

Additional Information:
  • Each tube of Filsuvez is for one-time use only. Once the tube is opened, use the product immediately
  • Discard the tube after use in household trash or through a drug take back site, if available
  • Subjects received topical treatment with either Filsuvez or a placebo gel on partial-thickness wounds every 1 to 4 days for a total of 90 days. Treated wounds were covered with non-adhesive dressings. Following completion of the double-blind phase, all subjects received FILSUVEZ for a total of 24 months during the open-label phase
  • If a Filsuvez- treated wound becomes infected, discontinue treatment to that wound until the infection has resolved
  • Apply Filsuvez to cleansed wounds with wound dressing changes until the wound is healed
Policy Updates:
  • 9/1/2024 (policy effective date) – New policy approved by WHA P&T Committee. (P&T, 8/20/2024) (P&T meeting date) 
References:
  1. Filsuvez Prescribing Information. Lichtenheldt GmbH Pharmazeutische Fabrik. Wahlstedt Germany. December 2023.
  2. Optum IPD Analytics. Available at: Dermatology: Epidermolysis Bullosa (ipdanalytics.com). Accessed March 25, 2024.
  3. About EB. Available at: https://www.debra.org/about-eb. Accessed March 25, 2024.
  4. Pfendner, E., and Lucky, A. Dystrophic Epidermolysis Bullosa. Available at: https://www.ncbi.nlm.nih.gov/books/NBK1304/#:~:text=Dystrophic%20epidermolysis%20bullosa%20(DEB)%20is,dystrophic%20epidermolysis%20bullosa%20(DDEB). Accessed March 25, 2024.
  5. Peraza, D. Epidermolysis Bullosa. Available at: https://www.merckmanuals.com/professional/dermatologic-disorders/bullous-diseases/epidermolysis-bullosa. Accessed March 25, 2024.
  6. What is EB. Available at: https://www.debra-international.org/what-is-eb#:~:text=EB%20is%20a%20group%20of,with%20more%20than%2030%20subtypes. Accessed March 25, 2024.
  7. ClinicalTrials.gov. Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa (EASE). Available at: https://www.clinicaltrials.gov/study/NCT03068780?cond=NCT03068780&rank=1#participation-criteria. Accessed March 25, 2024.
  8. UptoDate. Diagnosis of epidermolysis bullosa. Available at: https://www.uptodate.com/contents/diagnosis-of-epidermolysis-bullosa. Accessed March 25, 2024.
  9. UptoDate. Overview of the management of epidermolysis bullosa. Available at: https://www.uptodate.com/contents/overview-of-the-management-of-epidermolysis-bullosa?search=epidermolysis%20bullosa&source=search_result&selectedTitle=2%7E91&usage_type=default&display_rank=2. Accessed March 25, 2024.
  10. UptoDate. Epidermolysis bullosa: Epidemiology, pathogenesis, classification, and clinical features. Available at: https://www.uptodate.com/contents/epidermolysis-bullosa-epidemiology-pathogenesis-classification-and-clinical-features?search=epidermolysis%20bullosa&source=search_result&selectedTitle=1%7E91&usage_type=default&display_rank=1. Accessed March 25, 2024.
  11. Kern, J., Schwieger-Briel, A., Lowe, S., et al. Oleogel-S10 Phase 3 study “EASE” for epidermolysis bullosa: study design and rationale. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560757/. Accessed March 26, 2024.

Last review date: September 1, 2024

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone